Concord Biotech FY26 Results and Dividend Announcement

Concord Biotech reports FY26 Standalone Profit After Tax (PAT) of ₹263.27 crore and Consolidated PAT of ₹259.23 crore.

Reader Takeaway: Healthy PAT and dividend proposed; note one-time exceptional charge.

What just happened

Concord Biotech Limited has released its audited financial results for the financial year ended March 31, 2026. The company reported standalone revenue of ₹1,055.07 crore and standalone PAT of ₹263.27 crore. Consolidated revenue stood at ₹1,054.89 crore with a consolidated PAT of ₹259.23 crore. The company also announced a recommended final dividend of ₹7.55 per equity share.

An exceptional charge of ₹3.28 crore was recognized, relating to the statutory impact of new labour codes notified in November 2025. The company's statutory auditors, M/s. BSR & Co. LLP, issued an unmodified opinion on the financial results.

Why this matters

For investors, the declaration of a dividend provides a direct return on investment. The robust PAT figures indicate the company's profitability for the fiscal year. The unmodified audit opinion suggests the financial statements are reliable. The exceptional charge, while impacting the bottom line, is explained as a one-time regulatory event.

The backstory

Concord Biotech is a biopharmaceutical company. The current announcement pertains to its annual financial performance and corporate actions for the fiscal year 2025-26. The appointment of Mrs. Ekta Gupta as an Additional Independent Director also signifies a governance update.

What changes now

Shareholders will need to approve the recommended dividend at the upcoming Annual General Meeting. The company has set July 24, 2026, as the record date for dividend entitlement. The appointment of the new director will strengthen the board, subject to shareholder approval.

Risks to watch

The primary risk highlighted is the one-time exceptional charge of ₹3.28 crore related to new labour codes, which could impact short-term profitability perception. While considered non-recurring, investors should assess its ultimate effect.

Peer comparison

(No peer comparison data available in the filing)

Context metrics (time-bound)

• Standalone Revenue FY26: ₹1,055.07 crore
• Standalone PAT FY26: ₹263.27 crore
• Consolidated Revenue FY26: ₹1,054.89 crore
• Consolidated PAT FY26: ₹259.23 crore
• Dividend Recommended: ₹7.55 per equity share
• Exceptional Charge: ₹3.28 crore
• Dividend Record Date: July 24, 2026

What to track next

Investors should watch for the shareholder approval of the dividend and the subsequent payout. The company's ongoing performance in FY27, especially in light of the new labour codes, will also be crucial.